Abstract Library

#4650 Whole exome sequencing in pulmonary neuroendocrine neoplasms: Findings from a pilot investigation

Introduction: The molecular landscape of lung neuroendocrine tumours (NETs) is still poorly characterised. Lung NETs main prognostic factors currently include stage, histotype, grade, location, and demographic parameters, but molecular biomarkers are still not available, limiting the possibility for personalised therapeutic strategies.

Conference:

Presenting Author:

Authors: Martiradonna M, Pecora G, Mancini C, de Vitis C, Telese S,

Keywords: carcinoid, PBMC, NGS, Whole exome sequencing, WES, FFPE, Lung NET, molecular landscape,

#4384 The efficacy of combination of temozolomide and capecitabine for neuroendocrine tumours: A real-world comparison of outcomes in Alberta, Canada – Patients treated from 2011-2021

Introduction: The combination of capecitabine and temozolomide (CAPTEM) showed PFS benefits in pancreatic neuroendocrine tumours (PNETs).

Conference:

Presenting Author:

Authors: Aleksi A, Malek H, Husi P, Halperin H, White-Gloria C,

Keywords: captem, neuroendocrine tumour, endocrine tumour, progression-free survival, overall survival,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4289 Temozolomide-associated hypermutation and response to immunotherapy in advanced pulmonary neuroendocrine tumours

Introduction: Temozolomide (TMZ) cytotoxicity depends on an intact DNA mismatch repair (MMR) pathway and low levels of O6-methylguanine DNA methyltransferase (MGMT). However, absence of MGMT-mediated repair coupled with defective MMR (dMMR) may lead to enrichment of C:G to A:T transitions throughout the genome, a marked increase in tumour mutational burden (TMB), and loss of TMZ-induced cytotoxicity. This resistance mechanism is called TMZ-associated hypermutation (TAH). Theoretically, this effect could lead to sensitivity to checkpoint inhibitor immunotherapy.

Conference:

Presenting Author: Buikhuisen W

Authors: Buikhuisen W, Badrising S, Moonen L, Derks J, Monkhorst K,

Keywords: Pulmonary NET, whole genome sequencing, temozolomide signature, immunotherapy,

#4120 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): An international case series

Introduction: Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) is a rare disorder that is characterized by diffuse hyperplasia of bronchiolar and bronchial pulmonary neuroendocrine cells. The precise incidence and prevalence is unknown and the clinical course is not fully understood.

Conference:

Presenting Author: Almeamar H

Authors: Penugonda M, O'Callaghan M, Diesler R, O'Brien H, Almeamar H,

Keywords: DIPNECH, NET, neuroendocrine, pulmonary NET, Neuroendocrine cells hyperplasia,